NASDAQ:DXR - Nasdaq - US2394671034 - Common Stock - Currency: USD
NASDAQ:DXR (5/7/2025, 8:00:02 PM)
7.47
-0.11 (-1.39%)
The current stock price of DXR is 7.47 USD. In the past month the price increased by 0.27%. In the past year, price decreased by -21.8%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.02 | 232.31B | ||
ISRG | INTUITIVE SURGICAL INC | 70.18 | 192.17B | ||
BSX | BOSTON SCIENTIFIC CORP | 38.81 | 155.01B | ||
SYK | STRYKER CORP | 30.65 | 146.59B | ||
MDT | MEDTRONIC PLC | 15.57 | 106.66B | ||
BDX | BECTON DICKINSON AND CO | 11.86 | 47.99B | ||
EW | EDWARDS LIFESCIENCES CORP | 28.86 | 44.12B | ||
IDXX | IDEXX LABORATORIES INC | 42.69 | 39.43B | ||
RMD | RESMED INC | 26.95 | 35.88B | ||
DXCM | DEXCOM INC | 50.52 | 32.68B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 14.96 | 31.51B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 15.41 | 22.46B |
Daxor Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in New York City, New York. Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. The company specializes in blood volume measurement technology focused on blood volume testing innovation. The company markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. The company has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
DAXOR CORP
Suite 7120, 350 Fifth Avenue
New York City NEW YORK 10118 US
CEO: Joseph Feldschuh
Employees: 0
Phone: 12122440555
The current stock price of DXR is 7.47 USD. The price decreased by -1.39% in the last trading session.
The exchange symbol of DAXOR CORP is DXR and it is listed on the Nasdaq exchange.
DXR stock is listed on the Nasdaq exchange.
6 analysts have analysed DXR and the average price target is 25.5 USD. This implies a price increase of 241.37% is expected in the next year compared to the current price of 7.47. Check the DAXOR CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
DAXOR CORP (DXR) has a market capitalization of 36.83M USD. This makes DXR a Nano Cap stock.
DAXOR CORP (DXR) currently has 0 employees.
DAXOR CORP (DXR) has a resistance level at 7.76. Check the full technical report for a detailed analysis of DXR support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
DXR does not pay a dividend.
The PE ratio for DAXOR CORP (DXR) is 43.94. This is based on the reported non-GAAP earnings per share of 0.17 and the current share price of 7.47 USD. Check the full fundamental report for a full analysis of the valuation metrics for DXR.
The outstanding short interest for DAXOR CORP (DXR) is 0.49% of its float. Check the ownership tab for more information on the DXR short interest.
ChartMill assigns a technical rating of 2 / 10 to DXR. When comparing the yearly performance of all stocks, DXR is a bad performer in the overall market: 68.61% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to DXR. While DXR seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months DXR reported a non-GAAP Earnings per Share(EPS) of 0.17. The EPS increased by 574.51% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 447.75% | ||
ROA | 1.46% | ||
ROE | 1.5% | ||
Debt/Equity | 0.02 |
ChartMill assigns a Buy % Consensus number of 80% to DXR. The Buy consensus is the average rating of analysts ratings from 6 analysts.